glp 1 agonist comparison GLP-1 Agonists for Weight Loss: A Side-by-Side Comparing GLP-type therapies for weight

Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice

Hyperlink reference not valid

Relative to SU or dipeptidyl peptidase-4 therapy, dapagliflozin is estimated to be cost-effective below the generally accepted cost-effectiveness thresholds (Table 3)

10.1111/joim.13751 121 YaoY.XuX.JinL

The report found GLP-1 adoption has continued to increase across the United States, rising to 13.1% of US adults in June 2026 from 12% in November 2025

There is increasing interest in the 60-minute postload glucose concentration as a predictor of future T2D and a treatment target (9), and it is intuitively likely that the rate of gastric emptying is a key determinant